• 1
    Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland. 3.aktualisierte Ausgabe, Saarbrücken. 2002
  • 2
    Claude JC, Frentzel-Beyme RR, Kunz E. Occupation and risk of cancer of the lower urinary tract among men. A case-control study. Int J Cancer 1988; 41: 3719
  • 3
    Pesch B, Haerting J, Ranft U, Klimpel A, Oelschlägel B, Schill W. Occupational risk factors for urothelial carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Mulitcenter Urothelial and Renal Cancer Study. Int J Epidemiol 2000; 2: 23847
  • 4
    Rehn L. Blasengeschwülste bei Fuchsinarbeitern. Arch Klin Clin 1895; 50: 588600
  • 5
    Schulte PA, Ringen K, Hemstreet GP et al. Risk factors of BC in a cohort exposed to aromatic amines. Cancer 1986; 58: 215662
  • 6
    Popp W, Schmieding W, Speck M, Vahrenholz C, Norpoth K. Incidence of BC in a cohort of workers exposed to 4-chloro-o-toluidine while synthesizing chlordimeform. Br J Ind Med 1992; 49: 52931
  • 7
    Stasik MJ. Carcinomas of the urinary bladder in a 4-chloro-o-toluidine cohort. Int Arch Occup Environ Health 1988; 60: 214
  • 8
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 30314. Epub 2008 Apr 30. Review
  • 9
    Herr HW, Donat SM, Dalbagni G. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 2002; 168: 97880
  • 10
    Mowatt G, Zhu S, Kilonzo M et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of BC. Health Technol Assess 2010; 14: 1331
  • 11
    Feil G, Krause FS, Nelde HJ, Bichler K-H, Wechsel HW. Diagnosis of transitional cell carcinoma (TCC) of the BC: comparison if urinary cytology, BTA TRAK test, and NMP22 assay. Anticancer Res 1999; 19: 5743 (abs)
  • 12
    Lahme S, Bichler K-H, Feil G, Krause S. Comparison of cytology and nuclear matrix protein for the detection and follow-up of BC. Urol Int 2001; 66: 727
  • 13
    Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC-S. Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human BC. J Urol 1998; 52: 398402
  • 14
    Ramakumar S, Bhuiyan J, Besse JA et al. Comparison of screening methods in the detection of BC. J Urol 1999; 161: 38894
  • 15
    Bunting P, Fleshner N, Kapusta L, Hersey K, Kotz L. Detection of BC via non-invasive methods: a direct comparison of the NMP-22 and Immunocyt tests. J Urol 2000; 163 (Suppl.): 1335
  • 16
    Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 12130
  • 17
    Pesch B, Nasterlack M, Eberle F et al. The role of haematuria in BC screening among men with former occupational exposure to aromatic amines. BJU Int 2011; 108: 54652
  • 18
    Rodgers M, Nixon J, Hempel S et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 2006; 10: iiiiv, xi–259
  • 19
    Habuchi T, Marberger M, Droller MJ et al. Prognostic markers for BC: International Consensus Panel on bladder tumor markers. Urology 2005; 66 (Suppl. 1): 6474
  • 20
    Feil G, Bichler KH, Päulgen-Nelde HJ et al. Urinzytologie beim Harnblasenkarzinom. Diagnostische Wertigkeit eines neuen immunologischen Fluoreszenztestes. Urologe A 2003; 42: 5317
  • 21
    Rathert P. Urinzytologie beim Harnblasenkarzinom: Kritische Wertung. Urologe A 2003; 42: 90811
  • 22
    HVBG (Hrsg). BK-DOK '99. Dokumentation des Berufskrankheiten-Geschehens in Deutschland. Sankt-Augustin. 2001
  • 23
    Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population?: a cost per life-year saved analysis. Cancer 2006; 107: 98290
  • 24
    Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008; 2: 21221
  • 25
    Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for BC. J Urol 1999; 161: 625
  • 26
    Del Nero A, Esposito N, Currò A et al. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 BC: comparison with urinary cytology and BTA test. Eur Urol 1999; 35: 937
  • 27
    Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following BC: the prognostic value of false-positive results. BJU Int 2001; 88: 692701
  • 28
    Lokeshwar VB, Habuchi T, Grossman HB et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005; 66 (Suppl. 1): 3563
  • 29
    Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on BC: a critical review of the literature. BJU Int 2010; 105: 3008. Epub 2009 Nov 13
  • 30
    Atsü N, Ekici S, Oge OO, Ergen A, Hascelik G, Ozen H. false-positive results of the NMP22 test due to hematuria. J Urol 2002; 167: 5558
  • 31
    Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C. Guidelines on BC. The EAU working group on oncological urology. EurUrol 2002; 41: 10512
  • 32
    Herr HW, Donat SM, Dalbagni G. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 2002; 168: 97880
  • 33
    Shariat SF, Marberger MJ, Lotan Y et al. Variability in the performance of nuclear matrix protein 22 for the detection of BC. J Urol 2006; 176: 91926; discussion 926